- Director, Lung Transplantation, UH Cleveland Medical Center
- Associate Professor, CWRU School of Medicine
Dr. Robert Schilz is director of Pulmonary Vascular Disease and medical director of Lung Transplantation at University Hospitals Cleveland Medical Center. He is also an Associate Professor at Case Western Reserve University School of Medicine.
Dr. Schilz earned Doctor of Osteopathic Medicine (DO) and Doctor of Philosophy (PhD) degrees from the Michigan State University Medical Scientist Training program. He then completed a Residency and Chief Residency at the Cleveland Clinic in Cleveland, Ohio. He also completed Pulmonary & Critical Care and Research fellowships at Yale University. Prior to joining University Hospitals, Dr. Schilz was on staff at the Cleveland Clinic in Pulmonary and Critical Care Medicine.
For over 25 years, Dr. Schilz has participated in clinical and basic research in the areas of advanced lung diseases and pulmonary hypertension, with numerous publications in the areas of pulmonary hypertension, lung transplantation and advanced lung disease.
Dr. Schilz serves or has served as an advisor or committee member for a number of state, national and international organizations, including the International Society for Heart Lung Transplantation, American College of Chest Physicians, Pulmonary Hypertension Association and the Ohio State Board of Hospitals. He is a past Associate Editor of Advances in Pulmonary Hypertension and reviewer for a number of international journals. He has been consistently named as “One of America’s Best Doctors” since 2005.
- Chronic Obstructive Lung Disease
- Chronic Thromboembolic Disease
- Critical Care
- Diaphragm Pacing Surgery
- Lung Transplantation
- Lung Volume Reduction
- Pulmonary Hypertension
- Pulmonary Vascular Disease
Patient Experience Reviews
4.7 out of 5
Patient Comments (8)
Reviewed On 7/1/2021
Love Dr Schilz and his team They are always there for me
Reviewed On 5/1/2021
Reviewed On 5/1/2021
Everyone I had contact with was extremely nice, everything was explained to me. Dr Schilz and his team are the best!
Reviewed On 4/1/2021
*** Dr. Schilz is a great doctor.
Reviewed On 4/1/2021
Dr Shilz and his team are excellent. They provide life saving care and are always available if I need them.. Thank you.
Reviewed On 3/1/2021
Dr. Schilz is a brilliant man whom along with Dr. *** saved my life! I trust them implicitly with my care.
Reviewed On 11/1/2020
Excellent experience !
Reviewed On 10/1/2020
We love Dr. Schilz and staff. Dr. Schilz takes a personal interest in our family and goes above and beyond to keep us well. He is very knowledgeable on new and upcoming treatments. We are blessed to have him as our doctor.
- Critical Care Medicine - American Board of Internal Medicine
- Pulmonary Disease - American Board of Internal Medicine
Fellowship | Pulmonary/Critical Care
Pulmonary/Critical Care - Yale University School Of Medicine (1993 - 1996)
Residency | Internal Medicine/Chief Resident
Internal Medicine/Chief Resident - Cleveland Clinic (1992 - 1993)
Residency | Internal Medicine
Internal Medicine - Cleveland Clinic (1989 - 1992)
Internship | Internal Medicine
Internal Medicine - Sparrow Hospital (1988 - 1989)
Michigan State University College Of Human Medicine (1988)
University Of Wisconsin-Madison (1979)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Robert Schilz disclosed the following Outside Relationships with Industry:
- - Gilead - Consulting
- - SCS Healthcare - Consulting
- - United Therapeutics Corp - Consulting
- - Actelion Ltd. - Honoraria
- - Bayer Corporation - Honoraria
- - Genentech, Inc. - Honoraria